Needham analyst Rajvindra Gill maintains NVIDIA (NASDAQ:NVDA) with a Buy and raises the price target from $200 to $230.
Why This Illumina Analyst Is Bullish About NovaSeq X+
Illumina, Inc.’s (NASDAQ: ILMN) NovaSeq X Plus is likely to become “the ultimate genome machine,” lending upside in 2024 and beyond, according to SVB Securities.
